explore -WSS

explore

author：focus 2025-09-08 19:12:25 - browse：32854

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Home health providers sue Medicare over payment cuts

WSS

Pumping milk in bathrooms at health conferences is common

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

A pediatrician calls for Congress to pass the child tax credit deal

Medicare wants to send $9 billion to 340B hospitals

Printout prescription drug information shouldn’t go digital

Immunocompromised patients offer clues on chronic Covid

focus

explore

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Swim instructor mom warns parents not to buy blue swimsuits for kids

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price lawsuits could be good politics for Biden

Hepatitis C has a cure — but many Americans still lack access to it

Cardiologists urge adding sexual orientation, gender identity to health records

After affirmative action ruling, medical educators look to 'holistic review'

Cardiologists urge adding sexual orientation, gender identity to health records

ChatGPT in medicine: STAT answers readers' burning questions

Microsoft launches AI tool for clinical documentation through Epic

explore

Wisconsin governor employs partial veto to fund schools for 4 centuries

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Parents surprise family after baby discharged from NICU after 170 days

Home health providers sue Medicare over payment cuts

focus

focus

entertainment

knowledge